An observational study in Renal Replacement Therapy for Acute Kidney Injury in ICU, sponsored by University Hospital, Bordeaux. Recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Acute Kidney Injury with a site in France — 31 open to participants now, 35 under way, 4 of them phase 3. Acute Kidney Injury · France.
Among the 154 studies in Acute Kidney Injury with a site in France, this one is the 13th largest by planned enrollment of the 76 observational ones that give a count, is one of 9 that started in 2025, is one of 76 observational ones, reaches primary completion later than 23 of the 34 other live ones, and was the 145th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →31 of the 154 studies in Acute Kidney Injury with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Uppsala University · Sites in France, Australia, Brazil and 7 more countries
Ages 0–16
AstraZeneca · Sites in France, United States, Argentina and 11 more countries
Ages 18–80
Hospices Civils de Lyon · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 22 · Phase 4 5
First in 2004; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 150 across the 78 interventional studies, 190 across the 76 observational. Of the 106 that completed or were terminated, 8 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 154 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 6 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
11 of the studies in Acute Kidney Injury with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03329313University Hospital, MontpellierEffects of Variation of Sodium Dialysate in ICU | 2026-12-19 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT04264065Assistance Publique - Hôpitaux de ParisAlbumin and Prognosis of Severely Patients Burns | 2027-01-16 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
| NCT07596407Assistance Publique - Hôpitaux de ParisAcute Kidney Injury : Long-term Renal and Cardiovascular Prognosis and Biomarker-based Risk Assessment | 2027-05-30 |
Add all 11 to your calendar (.ics) → With an account.
Among the 154 studies in Acute Kidney Injury with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.
Tumor lysis syndrome (TLS) is a common and life-threatening complication in patients with hematologic malignancies, characterized by severe metabolic imbalances due to rapid tumor cell destruction. This syndrome frequently leads to acute kidney injury (AKI), requiring renal replacement therapy (RRT) in about 50% of cases. Despite its clinical significance, there is a lack of consensus on the optimal timing of RRT initiation in TLS-related AKI. Studies in other forms of AKI suggest no difference in outcomes between early and delayed RRT initiation, but these results are not directly applicable to TLS patients. This study seeks to fill this gap by analyzing the timing and outcomes of RRT initiation in TLS patients. The retrospective study will collect data from multiple intensive care units (ICUs) across France. Procedure: The study will retrospectively analyze patient data from 2013 to 2023, comparing early vs. delayed RRT initiation. Follow-up: Data on renal function, RRT usage, and mortality will be collected 30 days and one year after ICU admission.
This is a retrospective, multicenter cohort study conducted across several intensive care units (ICUs) in France. Data will be collected retrospectively from patient records and analyzed to assess the impact of early versus delayed RRT initiation on clinical outcomes in patients with TLS-induced AKI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with early initiation of RRT, RRT within 24 hours of acute kidney injury (AKI) diagnosis.
Patients with delayed initiation of RRT, RRT initiated only after urgent clinical indications arise, such as severe hyperkalemia or metabolic acidosis.
Renal dysfunction at ICU discharge
The primary outcome is renal dysfunction at ICU discharge, defined as a ≥25% increase in serum creatinine from baseline, assessed at the time of ICU discharge.
Time frame: From baseline to up to 30 days .
Incidence of AKI
Incidence of AKI related to Tumor lysis syndrome (TLS), assessed at ICU admission.
Time frame: At baseline
Use of RRT for TLS-related AKI
Use of RRT for TLS-related AKI, assessed during ICU stay.
Time frame: From baseline to up to 30 days.
Renal recovery
90-day renal recovery, assessed at 90 days post-admission.
Time frame: At 90 days after baseline
Long-term renal function
Long-term renal function is assessed by creatinine at one year
Time frame: 12 months after baseline
Mortality at 30 days
Mortality rate at 30 days.
Time frame: 30 days after baseline
Mortality at 12 months
Mortality rate 12 months post ICU admission
Time frame: 12 months after baseline
Long-term renal function
Long-term renal function is assessed by glomerular filtration rate at one year
Time frame: 12 months after baseline
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →